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Clinical Case Report and Review
ABSTRACT
Immune-mediated encephalitis as an adverse event due to checkpoint inhibitors is very rare. We describe herein the case of 
a 38-year-old woman with metastatic triple-negative breast cancer who developed seizures and somnolence twelve days 
after receiving the first dose of Atezolizumab. Work up ruled out all infectious etiologies, and the patient was eventually 
diagnosed with immune-mediated meningoencephalitis. Symptoms recovered with a high-dose of steroids, and she was 
found to have an excellent response on follow-up imaging, which raised the question of whether a relationship exists 
between the occurrence, and severity of the adverse event and the response to treatment. Only a few other cases of 
atezolizumab–related encephalitis have been published. Early recognition and treatment are crucial; the reason why we 
are describing this case along with a review of the literature and a review on all the neurological immune-related adverse 
events due to the different checkpoint inhibitors. 
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INTRODUCTION
In the past decade, immune checkpoint inhibitors 
(ICI) have changed the treatment paradigm of 
the solid tumors. The first breakthrough in cancer 
immunotherapy was the discovery of the cytotoxic 
T-lymphocyte-associated protein 4 (CTLA-4), and 
the first antibody directed against the CTLA-4, 
Ipilimumab, was approved in 2011 for the treatment 
of advanced Melanoma.1 Other checkpoint inhibitors 
targeting the interaction between the programmed 
cell death-1 (PD-1) on T-cell receptors and its ligand, 
the programmed death-ligand 1 (PDL-1) on tumor 
cells were then studied. These include (but are not 
limited to) Nivolumab and Pembrolizumab, which 
are PD-1 blockers, and Atezolizumab that blocks 
the PDL-1. By blocking these proteins, the inhibitory 
pathway is inactivated, thus unleashing the T-cells 
against antigens of the neoplastic cells. However, this 
over-exaggerated activation of the immune system 
can come with a price, and many immune-related 
adverse events (irAE) have been observed in clinical 
trials and in clinical practice. Neurologic irAE occurs 
less frequently than other irAE; however, it can, at 
times, be severe and sometimes fatal. We report a 
case of meningoencephalitis as an adverse event 
from Atezolizumab during the treatment of advanced 
metastatic triple-negative breast cancer along with a 
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review of possible neurological irAEs emerging with 
the growing use of ICI and immunotherapy in general.
CASE REPORT
A 38-year-old woman was diagnosed with 
locally advanced triple-negative breast cancer. She 
had no previous medical problems, no family history 
of malignancy, and was BRCA negative despite her 
young age. She was initially treated by a subcutaneous 
mastectomy with axillary lymph node dissection and 
was found to have a pT3N1 disease. She had no 
metastatic disease and thus was staged as IIIA and 
received adjuvant chemotherapy with Adriamycin and 
Cyclophosphamide followed by Docetaxel, followed by 
adjuvant radiotherapy.
Two years later, she was found to have recurrent 
metastatic disease, mainly in the right upper lung 
lobe and hilum, confirmed to be triple-negative breast 
adenocarcinoma by fine-needle aspiration (FNA) by 
ultrasound (EBUS). Since then, she received several lines 
of treatment with initially good response followed by a 
progression of the disease. These included Carboplatin 
and Paclitaxel, Bevacizumab, and Capecitabine, then 
Eribulin. She eventually progressed on Eribulin, with 
increasing cough and dyspnea, and a new lesion in the 
right lung compressing the airways.
PDL-1 testing on the FNA at that time was negative. 
However, the patient had an excellent performance 
status, and in view of very limited options, the decision 
was made to start with stereotactic radiation for 
symptomatic relief along with Atezolizumab. Nab-
Paclitaxel was planned to be added to Atezolizumab 
once radiotherapy was completed. This was based on 
a recent study that showed a progression-free survival 
benefit with the addition of Atezolizumab to Nab-
Paclitaxel in Advanced Triple-Negative Breast Cancer 
compared to Nab-paclitaxel alone. Patients included in 
the study who were PDL1 negative could still benefit 
from the addition of Atezolizumab, though to a lower 
extent than PDL-1 positive patients.2
Ten days after receiving the first dose of 
Atezolizumab, she developed fever refractory to 
antibiotics reaching 40 degrees Celsius. The fever was 
associated with nausea, vomiting, and headaches. 
Laboratory workup showed only leukopenia. Our 
working diagnosis was infectious versus immune-
mediated adverse effects from the immunotherapy. 
She was started on broad-spectrum antibiotics and 
antivirals. Workup at that time had shown negative 
IgM serologies for Parvovirus, CMV, and EBV, negative 
influenza rapid test, negative urine, and blood cultures, 
a low TSH but normal free T4 and T3, and a normal 
morning cortisol level. CT scan of the chest did not 
show any infiltrates or signs of infection. A couple 
of days later, the patient’s mental status acutely 
deteriorated; she became more somnolent and 
disoriented and then developed tonic-clonic seizures. 
She got intubated for airway protection and transferred 
to the intensive care unit (ICU). A magnetic resonance 
imaging (MRI) of the brain showed moderate diffuse 
leptomeningeal enhancement bilaterally (Figure 1). 
A lumbar puncture (LP) showed 15 white blood 
cells/mm3 with lymphocytosis of 80% lymphocytes, 
of which 26% were atypical, 79 mg/dl glucose, and 
60 mg/dl proteins. Cerebrospinal fluid (CSF) culture 
was negative, and cytology showed inflammatory 
cells only with no malignant cells. Polymerase chain 
reaction (PCR) multiplex for viral infections on CSF 
(adenovirus, CMV, EBV, HSV1, HSV2, Varicella-Zoster 
Virus, Enterovirus, Parechovirus, HHV6, HHV7, and 
parvovirus B19) was also negative.
The patient was diagnosed with an immune-
mediated meningoencephalitis in the absence of 
confirmed infectious etiology. She was started on 
high dose steroids with dexamethasone 24 mg daily 
(8 mg every 8 hours), which led to a dramatic and 
rapid improvement. She got extubated, progressively 
regained her normal level of consciousness in just a few 
days, and was discharged 2 weeks after admission with 
only mild lower extremity weakness and numbness. 
She continued her radiotherapy, but Atezolizumab was 
permanently discontinued. PET CT scan done 1 month 
after radiotherapy showed resolution of the large right 
infrahilar lobulated mass, which was 5.6 cm with SUV 
of 9.8 and a decrease in the SUV of the large cluster of 
avid right paratracheal lymph nodes from 15.5 to 6.8. 
All small bilateral cervical nodes and bilateral inguinal 
nodes had fully resolved (Figures 2 and 3).
As per the patient, the only thing that she recalled 
was that she presented to the emergency department 
for fever. She then woke up in the ICU without any 
awareness about what had happened. Recovery was 
tough, but she made it through with the help of her 
doctors, physical therapists, and her family. And even 
though she still had some lower extremity weakness 
and required a cane to ambulate, she was very thankful 
that she made it through.
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Her disease remained stable for around a year after 
that. Later, she progressed and developed metastatic 
brain disease, treated with radiotherapy, then 
eventually also progressed systemically. She received 
two other line of chemotherapy, but eventually, the 
decision was to stop treatment and focus on palliative 
care. Unfortunately, she passed away after 5 years after 
the initial diagnosis due to an infection.
Figure 1. Axial T2 FLAIR MRI sequences of the brain show a diffuse subtle hyper-intense signal of the sulci when done 
two weeks after the patient received Atezolizumab (A and C), suggestive of the leptomeningeal irritation (could be 
related to leptomeningeal spread of disease, meningitis, or an inflammatory process), and interval resolution of the 
sulcal hyper-intense signal after a few months (B and D). There was no abnormal intra-parenchymal signal on FLAIR.
4-9 Autops Case Rep (São Paulo). 2021;11:e2021261
Atezolizumab-induced encephalitis in a patient with metastatic breast cancer: a case report and review of neurological adverse events associated 
with checkpoint inhibitors
DISCUSSION
Immune checkpoints are a part of an inhibitory 
pathway of the immune system that controls the 
duration and amplitude of the immune response 
against a certain antigen. A major mechanism of 
resistance by tumors is through immune-checkpoint 
pathways, particularly against tumor specific T cells.3
Atezolizumab is a monoclonal antibody that 
targets PDL-1, which is expressed by tumor cells to 
avoid destruction by the immune system. It has already 
been used in urothelial, small cell, and non-small 
cell carcinomas but just recently got its approval for 
metastatic triple-negative breast cancer in 2019.2
All ICI can cause irAE as they produce an inflated 
inflammatory response. Some of the most common 
Figure 2. Axial lung window non-enhanced CT scan images of the chest show a significant decrease in the size 
of the right lower lobar lobulated metastatic mass post stereotactic radiation therapy and a dose of Atezolizumab 
(B) when compared to the images done prior (A).
Figure 3. MIP PET images performed prior to the administration of Atezolizumab (A) and around 4 months later 
(B) demonstrate resolution of the FDG avid mediastinal and hilar lymph nodes, with almost complete resolution of 
the right apical and lower lobar nodules. L: Left.
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events are skin-related (30%–55% of patients), like rash, 
pruritis or dermatitis, and gastrointestinal (12%–37% 
of patients) including diarrhea and colitis. However, 
neurological adverse events are rare with an incidence 
ranging from 3.8 to 6.1% with ICI monotherapy, 
and up to 12% with combination therapy, but the 
incidence of Grades 3 or higher events is <1%.4,5
Only a few cases of meningoencephalitis due to 
Atezolizumab have been reported in the literature 
(Table 1).
To our knowledge, only 7 cases have been reported 
at the time of this article, and they include two patients 
with bladder cancer, one with lung cancer, and another 
with cervical cancer.6-9 Three cases were also mentioned 
in the clinical trial of Atezolizumab in triple-negative 
breast cancer but have not been fully published, which 
makes our case the fourth breast cancer case.2
In all the published cases, the onset of neurological 
symptoms occurred 13 to 14 days after the 1st dose of 
Atezolizumab, as is the case in our patient, and they 
were all treated with steroids,6-8 except for one patient 
who did not respond to steroids alone, but responded 
to intravenous immunoglobulin (IVIG).9
All patients initially received empiric antibiotics 
and antivirals, as in our case. This is important especially 
at the time when the etiology of encephalitis is still not 
determined. In our case, we considered it to be due 
to Atezolizumab since all cultures and viral PCR were 
all negative. Leptomeningeal carcinomatosis was also 
ruled out by cytology, which was negative for malignant 
cells in the CSF. The paraneoplastic syndrome was 
unlikely as the neurologic symptoms occurred directly 
after she received the Atezolizumab, the number of 
lymphocytes was high in the CSF, and since all symptoms 
resolved quickly with the administration of steroids. 
Therefore, she was considered to have immune-
mediated meningoencephalitis. The Atezolizumab was 
discontinued permanently, as was the case in other 
published reports (grade 4 toxicity).
Neurological adverse events from 
immunotherapy
It is currently well-known that checkpoint 
inhibitors have a different toxicity profile than 
chemotherapy or targeted therapy. The incidence of 
irAE is also different between the different types of 
immunotherapy. CTLA-4 inhibitors have been shown 
to have higher rates and severity of irAEs than PD-1/L1 
inhibitors. Neurological irAE is quite uncommon and 
has been described more with the CTLA-4 inhibitors 
or with combination immunotherapy rather than with 
single-agent PD1-L1 inhibitors.4,10 The incidence of 
all neurological irAE with ipilimumab and nivolumab 
combination is around 14% and around 1 -3% with 
monotherapy.11
The autoimmune neurological events can affect 
the muscles, neuromuscular junction, nerves, routes, 
spinal cord, and brain, at variable severities, as described 
below. They mostly occur within the first 4 months after 
ICI administration but may arise at any time.10
Table 1. Similar Case reports of meningoencephalitis due to Atezolizumab in the literature, along with patient 




Therapy MRI CSF Outcome










27 Lung 78 13 days after 1st dose Steroids
No abnormal 
findings
high cell count 
of 139/μL Improved
38 Bladder 59 12 days after 1st dose Steroids
Unremarkable, 
Repeat MRI 






then died of 
progressive disease






50 white blood 
cells
Encephalitis resolved, 
died from disease 
progression and 
septic shock
CSF= cerebrospinal fluid; CNS= central nervous system; MRI= magnetic resonance imaging; y= years.
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Some of the mild (grade 1-2) neurological irAE 
that can occur include headaches, paresthesia, or 
small-fiber sensory neuropathies. They can occur 
in 6-12% of the patients, and there is no need to 
discontinue the ICI in these cases.
Grade 3 and 4 neurological irAEs include the 
following:
1) Myasthenia gravis
Myasthenia gravis (MG) is one of the most 
common neurological irAEs. It can occur either as 
de novo presentations (72%) or as an exacerbation 
of pre-existing myasthenia (18,2%). The average 
onset was 5 to 6 weeks post-treatment initiation, and 
around 60% of the cases were acetylcholine receptor 
autoantibodies (AChRAb) positive, while the remaining 
were negative.12 Interestingly, Anti-PD1, Nivolumab, 
and Pembrolizumab were the most often involved in 
immunotherapy. Common presentations do not differ 
from the idiopathic forms of MG and include ptosis, 
diplopia, and show fatigability on repetitive nerve 
stimulation testing.13
The prognosis of MG induced by ICI can be 
poor. In one review article, 14 out of 33 patients died 
after the diagnosis of MG. However, the prognosis 
did not seem to be related to the preexistence of 
myasthenia or to the presence of anti-acetylcholine 
receptor antibodies.14 Many patients required more 
than 1 treatment, they all received corticosteroids and 
prostigmine, but some of them required plasmapheresis 
and immunoglobulins. Rarely, azathioprine and 
mycophenolate mofetil were used.14
According to the National Comprehensive Cancer 
Network (NCCN) guidelines, management of grade 
2 toxicity includes first to hold the immunotherapy, 
then to start pyridostigmine and oral prednisone. 
Once symptoms improve, these agents can be tapered, 
and immunotherapy might be resumed. Grade 
3-4 symptoms will require hospitalization, immediate 
discontinuation of the immunotherapy (most often 
permanent), and higher doses of steroids. For patients 
who are refractory, plasmapheresis, or IVIG should 
be considered. All medications that can worsen MG 
should be avoided.15
2) Peripheral neuropathies
Immune-mediated polyneuropathies can occur 
either in an acute or chronic form. They have been 
mostly described as complications of ipilimumab but 
also of nivolumab or pembrolizumab to a lesser extent. 
Both sensory and motor peripheral neuropathies have 
been reported and are quite rare, occurring in less 
than 1% of patients. In grade 1 neuropathy, which 
is most cases, the immune checkpoint inhibitor can 
be continued with careful follow-up. However, if 
symptoms worsen and start interfering with daily 
activities, then it is advised to discontinue treatment 
and start steroids. GABA analogs can also be used for 
neuropathic pain control.15,16
3) Guillain Barre syndrome (GBS)
GBS induced by ICI is quite rare, with only a few 
cases reported in the literature. The agents implicated 
mostly were Ipilimumab and Nivolumab either alone 
or in combination. The presentation is typical for 
GBS, with sensory loss, quadriparesis, and areflexia, 
and the diagnosis was confirmed by lumbar puncture 
findings and Electromyography (EMG).17,18 In one case 
series, patients were treated with IVIG, corticosteroids, 
tacrolimus, or mycophenolate either alone or in 
combination. GBS was fatal in a few patients as 
3 out of 13 patients died of respiratory insufficiency 
and multiorgan failure.17,18 Idiopathic GBS treatment 
does not include corticosteroids; however, cases of 
GBS arising as an irAE have been reported to respond 
differently to steroid therapy than idiopathic GBS.18
Similarly, rare cases of Chronic inflammatory 
demyelinating polyradiculoneuropathy (CIDP) as an 
irAE have been described. Again, the agent responsible 
was mainly a combination Ipilimumab and Nivolumab, 
and unlike GBS, some patients initially presented with 
headaches and neuropathic pain in the extremities, 
and then were diagnosed with CIDP based on the 
evolution of the clinical picture, EMG, MRI, and LP 
findings. They were treated similarly to GBS with IVIG 
and corticosteroids, and outcomes were favorable.19
Current NCCN guidelines recommend treatment 
of immune-related GBS by either plasmapheresis or 
IVIG along with pulse methylprednisolone of 1 g daily 
for 5 days. Unlike MG, immunotherapy should be 
stopped permanently and cannot be resumed once 
the symptoms resolve.15
4) Aseptic Meningitis
Aseptic meningitis occurred in around 0.1 – 0.2% 
of patients, and typically 1 to 7 weeks after the first 
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dose of ICIs. Patients usually present with a stiff 
neck, fever, and headaches, but without any altered 
mental status. For diagnosis, it is essential to rule 
out all infectious causes. CSF findings typically show 
lymphocytic meningitis along with possibly meningeal 
enhancement on MRI. All reported cases of aseptic 
meningitis to date have recovered completely with 
steroids, and the agents responsible were mainly 
Ipilimumab and Nivolumab.10,20,21
Management of aseptic meningitis as per NCCN 
recommends holding the immunotherapy if mild to 
moderate, however, to permanently discontinue if 
severe. Treatment should include IV acyclovir until the 
viral infection is ruled out by PCR, and corticosteroids.15
5) Encephalitis
Among ICI-related irAEs, encephalitis is rare, 
but it may be severe and potentially fatal. It occurs in 
0.1 – 0.2% of patients, usually within days or few weeks 
after ICPI initiation. Most published cases were cases 
of melanoma in whom the encephalitis have occurred 
with the combination of ipilimumab and nivolumab.10
The presentation was typical of encephalitis 
but quite heterogenous as well; it included fever, 
headaches, altered mental status, confusion, gait 
instability, and seizures. The time of onset varied; in 
most of the cases, it occurred just a few days after the 
administration of the ICI, while in one case, for example, 
it was 297 days after its administration. The diagnosis 
was made by LP, which showed lymphocytosis, MRI 
findings which showed hyperintensity on T2 or were 
unremarkable, and by ruling out infectious etiologies 
by cultures and PCR. Most of the cases were treated 
empirically with antivirals and broad-spectrum 
antibiotics until an infectious process was ruled out 
and ultimately managed with intravenous steroids. 
Only a few patients required IVIG. The outcome was 
favorable in most cases, and symptoms resolved in a 
few days, but there are some rare cases reported where 
the encephalitis was fatal.5,16,20
As mentioned above in our case discussion, there 
were also 7 cases reported of encephalitis with the 
use of Atezolizumab. The outcome was favorable in 
all of them.
Based on these reports, current guidelines 
recommend stopping the immunotherapy and only 
consider rechallenge if the symptoms were mild and 
completely resolved. The treatment includes steroids, 
and IVIG can be considered if the symptoms do not 
resolve on corticosteroids alone. Rituximab can also 
be considered in severe cases or if no or limited 
improvement on the mentioned therapies.15
Predictor of disease response
Although our patient had a severe immune 
adverse reaction to the Atezolizumab, her continued 
remission after the meningoencephalitis could at 
least be partially related to a durable response to 
Atezolizumab. This raises the question of whether a 
relationship exists between the incidence and severity 
of the adverse events and the response to treatment.
There is some evidence that suggests that 
developing neurological irAE may be a positive 
predictor of disease response.13,21,22 In one cohort, 
the objective response rate was 70% in patients who 
developed neurological irAE, and the median overall 
survival was 45.7 months versus 11.2 months in those 
without neurological irAEs.13,21 In another case series, 
objective responses occurred in 50% of the patients 
(6/12) with 25% complete responses, despite the 
fact that these patients received high dose steroids to 
manage the toxicities.22
However, these are anecdotes and uncontrolled 
data, most of which occurred in patients with 
melanoma, so an accurate conclusion cannot be 
drawn, but the possibility that the development of 
neurological irAE may be associated with a better 
ORR remains.
CONCLUSION
As a conclusion, even though neurological irAEs 
are rare, it is important to recognize and manage them 
appropriately as they could be fatal. Encephalitis, in 
most cases, can be managed with steroids alone with 
an excellent prognosis. The question remains whether 
the occurrence of neurological irAE and its severity can 
be related to a better tumor response or not.
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